Valuation: Poxel

Market Cap 12.57M 14.47M 11.68M 10.77M 20.28M 1.38B 20.65M 138M 54.12M 686M 54.36M 53.17M 2.31B P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 79.65M 91.7M 73.97M 68.22M 128M 8.75B 131M 876M 343M 4.35B 344M 337M 14.62B EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day+0.85%
1 week+0.75%
Current month-0.98%
1 month-0.98%
3 months-21.60%
6 months-39.67%
Current year-13.89%
1 week 0.2
Extreme 0.1998
0.21
1 month 0.19
Extreme 0.1942
0.21
Current year 0.19
Extreme 0.1942
0.48
1 year 0.19
Extreme 0.1942
0.56
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
6.84
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 09/06/2026
Director of Finance/CFO - 30/11/2022
Corporate Officer/Principal - 30/04/2023
Director TitleAgeSince
Chairman - 30/07/2025
Director/Board Member - 30/07/2025
Director/Board Member - 30/07/2025
Date Insider Type Main position Quantity % Market Cap.
04/02/22 Fiscal year

Founder

67,000 0.2334%
04/02/22 Fiscal year

Founder

6,666 0.0232%
30/01/21 Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
+0.85%+0.75%-64.02%-67.76% 12.22M
-3.74%-6.32%+42.70%+63.37% 55.2B
-0.81%-0.33%+27.15%+81.12% 55.6B
-0.36%+0.55%-15.88%-14.97% 23.51B
-2.40%-6.72%-4.74%+353.58% 22.35B
-4.01%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.15%+26.00%-33.84% 17.45B
-3.34%-6.96%+22.02%+515.48% 15.16B
+0.57%-0.18%+50.73%+181.84% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -1.96%-1.38%+24.83%+133.83% 23.75B
Weighted average by Cap. -2.24%-0.46%+30.41%+121.21%

Financials

2023 2024
Net sales 1.98M 2.28M 1.84M 1.7M 3.2M 218M 3.25M 21.78M 8.53M 108M 8.56M 8.38M 364M 6.64M 7.64M 6.16M 5.68M 10.71M 729M 10.9M 72.96M 28.56M 362M 28.69M 28.06M 1.22B
Net income -35.09M -40.4M -32.59M -30.05M -56.61M -3.86B -57.63M -386M -151M -1.92B -152M -148M -6.44B -18.3M -21.07M -17M -15.68M -29.53M -2.01B -30.06M -201M -78.79M -999M -79.14M -77.41M -3.36B
Net Debt 46.42M 53.45M 43.11M 39.76M 74.89M 5.1B 76.25M 510M 200M 2.53B 201M 196M 8.52B 67.08M 77.23M 62.29M 57.45M 108M 7.37B 110M 737M 289M 3.66B 290M 284M 12.31B
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
30/07/26 0.2015 +0.85% 123,537
29/07/26 €0.1998 -0.10% 95,449
28/07/26 €0.2000 -0.25% 47,196
27/07/26 €0.2005 -0.25% 118,353
24/07/26 €0.2010 +0.50% 47,539
  1. Stock Market
  2. Stocks
  3. POXEL Stock